On October 8, 2018 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported it will present data on its investigational BTK inhibitor zanubrutinib and its investigational PARP inhibitor pamiparib at two upcoming medical meetings (Press release, BeiGene, OCT 8, 2018, View Source;p=irol-newsArticle&ID=2370698 [SID1234529823]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zanubrutinib clinical data will be included in an oral presentation at the 10th International Workshop on Waldenström’s Macroglobulinemia (IWWM). The IWWM meeting is taking place in New York City from October 11th to 13th, 2018.
Pamiparib clinical data will be included in a poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2018 Congress, which will take place October 19th to 23rd in Munich, Germany.
IWWM Oral Presentation:
Title: Improved Depth of Response With Increased Follow-up in Phase 1 Trial of Patients with Waldenström Macroglobulinemia (WM) Treated With Oral Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib (BGB-3111)
Session ID: Session X
Location: Main Area
Date: October 12, 2018
Time: 12:45 pm ET
Presenter: Constantine Tam, M.D., Director of Hematology, St. Vincent’s Hospital and Consultant Hematologist, Peter MacCallum Cancer Center
ESMO Poster Presentation:
Title: Preliminary Results of Pamiparib (BGB-290), a PARP1/2 Inhibitor, in Combination with Temozolomide (TMZ) in Patients With Locally Advanced or Metastatic Solid Tumors
Presentation #: 421P
Session ID: Poster display session (ID 258)
Location: Hall A3 – Poster Area Networking Hub
Date: October 22, 2018
Time: 13:15 to 14:15 CEST
Presenter: Melissa Johnson, M.D., Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute
About Zanubrutinib
Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in a broad pivotal clinical program globally and in China as a monotherapy and in combination with other therapies to treat various lymphomas.
About Pamiparib
Pamiparib (BGB-290) is an investigational inhibitor of PARP1 and PARP2 which has demonstrated pharmacological properties such as brain penetration and PARP-DNA complex trapping in preclinical models. Discovered by BeiGene scientists in Beijing, pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.